{"id":"NCT00866294","sponsor":"GlaxoSmithKline","briefTitle":"Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)","officialTitle":"A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2009-03-20","resultsPosted":"2010-11-15","lastUpdate":"2017-01-30"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder"],"interventions":[{"type":"DRUG","name":"paroxetine IR 10mg tablet","otherNames":[]},{"type":"DRUG","name":"paroxetine IR 20mg tablet","otherNames":[]},{"type":"DRUG","name":"matched placebo to paroxetine IR 10mg or 20mg","otherNames":[]},{"type":"DRUG","name":"Paroxetine CR 12.5mg tablet","otherNames":[]},{"type":"DRUG","name":"Paroxetine CR 25mg tablet","otherNames":[]},{"type":"DRUG","name":"matched placebo to paroxetine CR 12.5mg or 25mg","otherNames":[]}],"arms":[{"label":"paroxetine CR group","type":"EXPERIMENTAL"},{"label":"paroxetine IR group","type":"OTHER"},{"label":"placebo group","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of controlled-release (CR) formulation of paroxetine orally administered to patients with major depressive disorder (MDD) at a dose level in the range of 25 - 50 mg/day (initial dose level, 12.5 or 25 mg/day) once daily after evening meal for 8 weeks based on the decrease in HAM-D (Hamilton Depression Rating Scale) total score, to evaluate the safety based on adverse events, laboratory data and vital signs, and to describe the efficacy and safety of immediate release (IR) formulation of paroxetine.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8","timeFrame":"Baseline (Week 0) and Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-10.4,"sd":0.62},{"arm":"Paroxetine CR","deltaMin":-12.8,"sd":0.61},{"arm":"Paroxetine IR","deltaMin":-12.5,"sd":0.78}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":25},"locations":{"siteCount":67,"countries":["Japan","South Korea"]},"refs":{"pmids":["21895859"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":172},"commonTop":["Nausea","Nasopharyngitis","Withdrawal syndrome","Constipation","Headache"]}}